CARCINOID-SYNDROME AND SEROTONIN - THERAPEUTIC EFFECTS OF KETANSERIN

被引：20

作者：

ROBERTSON, JIS

机构：

[1] Department of Medicine, Prince of Wales Hospital, Chinese University of Hong Kong, Beerse

[2] Janssen Research Foundation, Beerse

来源：

CARDIOVASCULAR DRUGS AND THERAPY | 1990年 / 4卷

关键词：

5-hydroxytryptophan; biliary tumors; bronchial tumors; carcinoid heart disease; catecholamines; flushes; gut tumors; histamine; kinins; pancreatic tumors; serotonin antagonists; somatostatin;

D O I：

10.1007/BF00053427

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The carcinoid syndrome can arise when effluent blood from carcinoid tumor tissue gains access to the systemic, as opposed to the protal, venous system. Features include facial flushing, diarrhea, wheezing, right-sided cardiac lesions, and retroperitoneal fibrosis. Attacks of flushing, diarrhea, and wheezing can be provoked by bolus injections of adrenaline, noradrenaline, or pentagastrin. While serotonin usually predominates, carcinoid tumors can also secrete, in varying proportions, 5-hydroxytryptophan, kallikrein, kinins, substance P and other neuropeptides, prostaglandins, catecholamines, and histamine. Of these, serotonin, kinins, histamine, and substance P are possible mediators of flushes; serotonin and substance P of hyperperistalsis; and serotonin, kinins, or histamine of bronchial constriction. Despite the gross excess of circulating serotonin, nearly all is platelet bound and therefore inactive. Very little is free in plasma. Demonstration of a contribution of serotonin to carcinoid attacks requires assay of free plasma serotonin; measurements of whole blood or serum serotonin are of little value. Some, but not all, provoked flushes have been shown to be accompanied by a rise in free plasma serotonin or substance P; an increase in circulating kinins has been more consistently shown. The 5HT2 antagonist ketanserin has been found to inhibit both provoked and spontaneous attacks of flushing, diarrhea, and dyspnea in a proportion of patients with carcinoid syndrome. Intravenous ketanserin has controlled attacks of systemic hypertension during anesthesia and operation, and should also be useful in these circumstances for the relief of pulmonary hypertension or bronchial constriction. Because of the diversity and variability of hormones produced to excess in the carcinoid syndrome, a wide range of drugs is necessary for its treatment. Ketanserin is a valuable addition to the therapeutic repertoire in this fascinating, but often distressing, disease. © 1990 Kluwer Academic Publishers.

引用

页码：53 / 58

页数：6

共 30 条

[21]

Fischler M., Dentan M., Westerman M.N., Vourch G., Freitag B., Prophylactic use of ketanserin in a patient with carcinoid syndrome, Br J Anaesth, 55, (1983)

[22]

Houghton K., Carter J.A., Peri-operative management of carcinoid syndrome using ketanserin, Anaesthesia, 41, pp. 596-599, (1986)

[23]

Castheley P.A., Jablons M., Griepp R.B., Ergin M.A., Goodman K., Ketanserin in the pre-operative and intra-operative management of a patient with carcinoid tumor undergoing tricuspid valve replacement, Anesth Analg, 65, pp. 809-811, (1986)

[24]

Demoulin J.C., Bertholet M., Soumagne D., David J.L., Kulbertus H.E., 5-HT<sub>2</sub> receptor blockade in the treatment of heart failure, Lancet, 1, pp. 1186-1188, (1981)

[25]

Maton P.N., Camilleri M., Griffin G., Allison D.J., Hodgson H.J.F., Chadwick V.S., Role of hepatic arterial embolisation in the carcinoid syndrome, Br Med J, 287, pp. 932-935, (1983)

[26]

Peart W.S., Robertson J.I.S., The effect of a serotonin antagonist, methysergide (UML 491), in carcinoid disease, Lancet, 2, pp. 1172-1174, (1961)

[27]

Noppen M., Jacobs A., Van Belle S., Herregodts P., Somers G., Inhibitory effects of ranitidine on flushing and serum serotonin concentrations in carcinoid syndrome, Br Med J, 296, pp. 682-683, (1988)

[28]

Oberg K., Funa K., Alm G., Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome, N Engl J Med, 309, pp. 129-133, (1983)

[29]

Stahl S.M., Levin B., Freedman D.X., Serotonin depletion by fenfluramine in the carcinoid syndrome, N Engl J Med, 306, (1982)

[30]

Kvols L.K., Moertel C.G., O'Connell M.J., Schutt A.J., Rubin J., Hahn R.G., Treatment of the malignant carcinoid syndrome: Evaluation of a long-acting somatostatin analogue, N Engl J Med, 315, pp. 663-666, (1986)

← 1 2 3 →